Novo Nordisk Pharmaceutical Industries, Inc. (NNPII)
The insulin production process at NNPII includes product formulation with the mixing of human insulin crystals and chemical stabilizers and ultra-pure water, aseptic filling of glass vials or cartridges, inspection and packaging. The Clayton site also assembles and packages the FlexPen® disposable insulin device for the US market.
In addition to our production facilities, the site houses administration and laboratories for quality assurance of raw materials, in-process testing, and finished products.
This website aims to provide you with information about NNPII and its parent company Novo Nordisk A/S. Most sections contain an overview of a particular topic. Look for links for more in-depth information.